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Ferroquine (FQ; SSR97193), a ferrocene-containing 4-aminoquinoline derivate, has potent in vitro efficacy
against chloroquine (CQ)-resistant Plasmodium falciparum and CQ-sensitive P. vivax. In the current study, ex
vivo FQ activity was tested in multidrug-resistant P. falciparum and P. vivax field isolates using a schizont
maturation assay. Although FQ showed excellent activity against CQ-sensitive and -resistant P. falciparum and
P. vivax (median 50% inhibitory concentrations [IC50s], 9.6 nM and 18.8 nM, respectively), there was signif-
icant cross-susceptibility with the quinoline-based drugs chloroquine, amodiaquine, and piperaquine (for P.
falciparum, r  0.546 to 0.700, P < 0.001; for P. vivax, r  0.677 to 0.821, P < 0.001). The observed ex vivo
cross-susceptibility is likely to reflect similar mechanisms of drug uptake/efflux and modes of drug action of
this drug class. However, the potent activity of FQ against resistant isolates of both P. falciparum and P. vivax
highlights a promising role for FQ as a lead antimalarial against CQ-resistant Plasmodium and a useful
partner drug for artemisinin-based combination therapy.
The public health importance of Plasmodium vivax has been
neglected despite causing an estimated 70 to 391 million clin-
ical infections each year (2, 20, 24). Once regarded as a benign
infection, there is increasing evidence that vivax malaria is an
important cause of morbidity and developmental impairment,
inflicting a huge socioeconomic burden on countries of disease
endemicity (3, 20). In addition, recent reports about severe and
fatal vivax malaria (15, 30) raise the possibility of an emerging
threat of severe disease associated with partially effective treat-
ment (23). Chloroquine (CQ)-resistant (CQR) P. vivax is now
widespread across much of the areas of malaria endemicity,
and there are calls for artemisinin-based combination therapy
(ACT) to be deployed for both P. falciparum and P. vivax (14).
In areas of coendemicity of P. falciparum and P. viva, this
treatment approach combines the fast-acting artemisinin com-
pound with a partner drug with a longer half-life, such as
4-aminoquinolines, that have a proven efficacy in both species.
Ferroquine (FQ; SSR97193) is an organometallic drug
which contains a ferrocenyl group covalently flanked by a
4-aminoquinoline and a basic alkylamine. Among the more
than 100 ferrocene analogues synthesized and screened to date
(7, 8, 13), FQ proved to be the best antimalarial candidate. In
vivo experiments performed on rodent Plasmodium species
demonstrated powerful activity of the drug and a high oral
bioavailability, two major qualities for selecting lead com-
pounds for further development (6, 11). In vitro susceptibility
of FQ has been tested in different culture-adapted P. falcipa-
rum strains (5, 11, 12) and field isolates from Gabon, Africa,
Senegal, Cambodia, and Thailand (1, 4, 9, 21, 22) and has
proven to be effective against CQ-sensitive (CQS) and CQR
strains. More recently, the ex vivo activity of FQ against
chloroquine-sensitive strains of P. vivax has been demonstrated
in Thailand (19).
In several studies, weak cross-reactivity with CQ has been
described in P. falciparum isolates (1, 4, 9, 21, 22). However,
other studies have not observed significant correlation of in
vitro drug responses between FQ and other standard drugs
(16, 19).
The objectives of the current study were to examine the
species-specific ex vivo susceptibility of FQ in clinical isolates of
P. falciparum and P. vivax from an area with known multidrug
resistance in both species and to investigate cross-susceptibility
patterns with conventional antimalarials CQ, amodiaquine
(AQ), and piperaquine (PIP).
Plasmodium isolates were collected between September
2008 and December 2009 from patients attending malaria clin-
ics in Timika, Papua Province, Indonesia, a region where mul-
tidrug-resistant strains of P. vivax and P. falciparum are en-
demic (17, 25, 26, 29). Patients were recruited into the study if
presenting with symptomatic malaria and single infection with
P. falciparum or P. vivax, with a parasitemia of between 2,000
l1 and 80,000 l1, and a majority (50%) of parasites at
the ring stage of development. Patients treated with antima-
larials in the past month were excluded from this study. Ve-
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nous blood samples (5 ml) were collected by venepuncture,
and after removal of host white blood cells by using CF11
cellulose (27), packed infected red blood cells (IRBC) were
used for the ex vivo drug susceptibility assay.
Drug susceptibilities of P. vivax and P. falciparum isolates
were measured using a protocol modified from the WHO mi-
crotest, as described previously (28). Standard antimalarial
drugs CQ, AQ (Sigma-Aldrich, Australia), and PIP (Ranbaxy
Lab. Ltd., Gurgaon, India) and experimental compound FQ
(Sanofi-Aventis, Paris, France) were prepared as 10 mM stock
solutions in dimethyl sulfoxide (DMSO). Drug plates were
predosed by diluting the compounds in 50% ethanol followed
by lyophilization and stored at 4°C. The drug plate quality
control was assessed by defining drug response profiles in CQ-
resistant and -sensitive laboratory strains K1 and FC27, respec-
tively, before and after completion of the study.
Two hundred microliters of a 2% hematocrit blood media
mixture (BMM), consisting of RPMI 1640 medium plus 10%
AB human serum (P. falciparum) or McCoy’s 5A medium
plus 20% AB human serum (P. vivax), was added to each well
of predosed drug plates containing 11 serial concentrations
(2-fold dilutions) of the antimalarials (maximum concentra-
tions shown in parentheses) CQ (2,992 nM), AQ (80 nM), PIP
(769 nM), and FQ (590 nM). A candle jar was used to mature
the parasites at 37.5°C for 30 to 56 h. Incubation was stopped
when 40% of ring-stage parasites had reached the mature
schizont stage in the drug-free control well.
Thick blood films made from each well were stained with 5%
Giemsa solution for 30 min and examined microscopically. The
number of schizonts per 200 asexual stage parasites was deter-
mined for each drug concentration and normalized to the
control well.
The dose-response data were analyzed using nonlinear re-
gression analysis (WinNonlin 4.1; Pharsight Corporation) and
the median 50% inhibitory concentration (IC50) was derived
using an inhibitory sigmoid maximum effect (Emax) model.
Derived IC50 data were used only from predicted curves for
which the Emax and minimum effect (E0) were within 15% of
100 or 0, respectively.
Analysis was performed using STATA software (version
10.1; Stata Corp., College Station, TX). The Mann-Whitney U
test, Wilcoxon signed-rank test, and Spearman rank correla-
tion were used for nonparametric comparisons and correla-
tions; all data were log transformed for parametric analyses of
covariance.
Ethical approval for this study was obtained from the ethics
committees of the National Institute of Health Research and
Development, Ministry of Health, Indonesia, and the Menzies
School of Health Research, Darwin, Australia.
Ex vivo susceptibility of FQ (SSR97193) was tested in field
isolates obtained from 120 patients presenting with single-
species infections of either P. falciparum (n  60) or P. vivax
(n  60). Susceptibility profiles of the same isolates were also
tested against CQ, AQ, and PIP. Adequate growth for harvest
was achieved in 85% (50/59) of P. falciparum isolates and 86%
(51/59) of P. vivax isolates. Baseline characteristics of the iso-
lates processed are presented in Table 1, and the median IC50s
of each drug for the two species are presented in Table 2. Since
previous studies have highlighted a major difference in the
stage-specific activities of CQ and AQ, the same analysis for P.
vivax was restricted to isolates with 80% of asexual forms at
ring stage at the start of the assay (39/51, 76%). However, no
statistically significant difference in median IC50s for any of the
TABLE 1. Baseline characteristics of isolates for which ex vivo assay was accomplished
Baseline characteristica
Value for:
P. falciparum P. vivax
Total no. of isolates reaching harvest/total no. of isolates (%) 50/59 (85) 51/59 (86)
Median delay (range) from venepuncture to start of culture (min) 122.5 (45–246) 111 (35–200)
Median duration (range) of assay (h) 46 (32–56) 47 (41–50)
Geometric mean parasitemia (no. of asexual parasites/l) (95% CI) 13,582 (9,800–18,822) 9,914 (7,739–12,700)
Mean schizont count at harvest (95% CI) 41 (38–44) 38 (34–41)
Median initial % of parasites (range) at ring stage 100 (100–100) 90 (52–100)
a CI, confidence interval.
TABLE 2. Overall ex vivo activity for each drug according to the species tested
Drug
IC50 (nM) for
P. falciparum lab linea P. falciparum, clinical field isolates P. vivax, all isolates P. vivax, isolates with 80% rings
FC27 (CQS) K1 (CQR) No. ofassays (%)b
Median IC50
(nM) (range)
No. of
assays (%)b
Median IC50
(nM) (range)
No. of
assays (%)b
Median IC50
(nM) (range)
Chloroquine 28.2 170.5 50/50 (100) 94.9 (7.9–336.1) 50/51 (98)c 92.0 (12.9–386.5) 39/39 (100) 97.3 (12.9–386.5)
Amodiaquine 23.1 23.2 35/36 (97)d 12.3 (1.1–49.5) 32/32 (100) 16.9 (5.6–51.5) 24/24 (100) 21.0 (5.6–51.5)
Piperaquine 49.4 54.3 50/50 (100) 21.8 (0.3–63.9) 51/51 (100) 23.1 (1.3–93.4) 39/39 (100) 23.4 (1.3–93.4)
Ferroquine 18.6 20.7 44/45 (98)d 9.6 (0.6–71.5) 48/48 (100) 18.8 (1.6–48.9) 37/37 (100) 20.4 (1.6–48.9)
a Mean IC50s (derived from 2 independent experiments) assessed by in vitro schizont maturation and quantified by microscopy. CQS, chloroquine sensitive; CQR,
chloroquine resistant.
b Total number of assays with acceptable IC50s/total number of assays harvested (%).
c One highly resistant P. vivax isolate (i.e., model was not possible).
d Model not possible for 1 P. falciparum isolate.
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drugs tested was found between isolates with 80% and 50 to
80% ring stages, respectively.
The median IC50 for FQ against P. vivax was 18.8 nM (range,
1.6 to 48.9), compared to 9.6 nM against P. falciparum (range,
0.6 to 71.5; P  0.045). There was no correlation between the
IC50 and initial parasitemia for either species. Significant cross-
susceptibility was observed between FQ and the quinoline-
based drugs CQ, AQ, and PIP for both P. falciparum (r 0.546
to 0.700; P 0.001) and P. vivax (r 0.677 to 0.821; P 0.001)
(Fig. 1), and these correlations remained after controlling for
initial parasitemia (18).
Ferroquine is a promising, novel ferrocene 4-aminoquinoline
with potent in vitro activity against CQ-sensitive (CQS) and -re-
sistant (CQR) P. falciparum strains from various geographical
areas (4, 9, 18, 21, 22) as well as good in vivo efficacy in rodent
malaria (6, 11). A recent report of ex vivo drug susceptibility of P.
vivax on the Thai-Burmese border supports the further develop-
ment of this lead antimalarial compound (19).
In the current study, cross-susceptibility patterns of FQ in
clinical isolates of P. falciparum and P. vivax in an area highly
prevalent for multidrug resistance in both species were as-
sessed (17, 25, 26). We observed FQ IC50s in the low nM range
for both CQR and CQS P. falciparum isolates, in line with
previous reports from Africa and Southeast Asia (4, 9, 18, 21,
22). The ex vivo activity of FQ against multidrug-resistant P.
vivax isolates from Papua, Indonesia (median IC50  18 nM),
was comparable to the IC50 (median  15 nM) recently ob-
served against P. vivax isolates from the Thai-Burmese border
where most isolates are chloroquine sensitive (19). Our study
provides data of FQ activity in isolates with a greater range of
CQ susceptibility and highlights significant cross-susceptibility
between FQ and the conventional quinolines CQ, AQ, and
PIP. Our methodology controls for variation in the initial he-
matocrit but does not control for an inoculum effect which has
been reported to confound the in vitro assessment of drug
susceptibility in P. falciparum (18). We found no correlation
between initial parasitemia and IC50 in either of the species,
and the correlations between drugs remained after controlling
for initial parasitemia.
The observed cross-susceptibility patterns are consistent
with quinoline-based drugs sharing a common mode of action.
However, the within-species differences of the median IC50s of
CQ, AQ, PIP, and FQ indicate that there are likely to be other
mechanisms such as drug uptake, metabolism, and efflux, or
FIG. 1. Correlation of in vitro drug susceptibility of FQ and quinoline-based standard antimalarials in multidrug-resistant clinical isolates of P.
falciparum (A) and P. vivax (B) from Papua, Indonesia. FQ, ferroquine; CQ, chloroquine; AQ, amodiaquine; PIP, piperaquine; r, Spearman rank
correlation coefficient. (a) FQ versus CQ; (b) FQ versus AQ; (c) FQ versus PIP.
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resistance, involved in determining ex vivo drug responses to
these drugs.
The strong activity of FQ on CQR isolates of P. falciparum
and P. vivax suggests significant differences in the resistance
mechanisms of the parasites. For P. falciparum, previous stud-
ies have shown that FQ activity is independent of known mu-
tations in CQR relevant genes (10, 16, 18). Although FQ-
resistant laboratory strains have not yet been produced (10),
further studies elucidating the cause of activity of FQ on CQR
strains will help to shed light on possible parasite resistance
mechanisms to both drugs.
In conclusion, our data showing excellent ex vivo activity of
FQ against multidrug-resistant isolates of both P. falciparum
and P. vivax further support the potential use of FQ against
malaria in regions where both Plasmodium species are en-
demic.
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